Drugs / ATL-DC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01204684 | Oct 2010 → Aug 2024 | anaplastic astrocytoma, anaplastic oligoastrocytoma, glioblastoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATL-DC | “Autologous tumor lysate-pulsed dendritic cell (ATL-DC) vaccination is a promising immunotherapy for patients with high grade gliomas” PMID 37790490 ↗ Sep 2023 |
| Known as | autologous tumor lysate-pulsed dendritic cell | “Autologous tumor lysate-pulsed dendritic cell (ATL-DC) vaccination is a promising immunotherapy for patients with high grade gliomas” PMID 37790490 ↗ Sep 2023 |
| Modality | Cell therapy | “Autologous tumor lysate-pulsed dendritic cell (ATL-DC) vaccination is a promising immunotherapy for patients with high grade gliomas” PMID 37790490 ↗ Sep 2023 |